{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:52:23Z","timestamp":1771512743962,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Pathol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ibrutinib is a Bruton tyrosine kinase inhibitor used to treat many hematologic conditions, most commonly B\u2010cell lymphomas and leukemias. Reportedly, skin rash is an adverse event in up to 27% of treated patients. Histopathologic description of these lesions is limited. We present two cases of ibrutinib\u2010associated skin toxicities showing diverse histopathologic features. Case 1: A 72\u2010year\u2010old man was started on ibrutinib for chronic lymphocytic leukemia. Two months later, he developed multiple erythematous crusted papules on the chest, abdomen, and extremities. Biopsies revealed varied histopathology including poorly formed granulomatous dermatitis, epidermal necrosis, ulceration, and panniculitis. Ibrutinib was discontinued and his skin lesions resolved within 1 month. Case 2: A 48\u2010year\u2010old man received ibrutinib after failing standard therapy for primary central nervous system EBV positive diffuse large B\u2010cell lymphoma. Two months after initiation of ibrutinib, he developed multiple firm, red, non\u2010tender nodules on the forehead, buttock, and thigh. Biopsies revealed \u201cpseudolymphoma\u201d\u2010like reaction with dense pandermal lymphohistiocytic inflammation and granulomas. His skin toxicity resolved without cessation of therapy. Awareness of the spectrum of histopathologic features that may be encountered in skin lesions of patients treated with ibrutinib, as illustrated by these two cases, will be critical for optimal patient management.<\/jats:p>","DOI":"10.1111\/cup.14160","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T20:45:28Z","timestamp":1635885928000},"page":"363-368","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ibrutinib skin toxicities: Report of two cases"],"prefix":"10.1111","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7187-8342","authenticated-orcid":false,"given":"Maria Suzanne","family":"Bloomquist","sequence":"first","affiliation":[{"name":"Department of Pathology and Immunology Baylor College of Medicine  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Pathology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhuvaneswari","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology Baylor College of Medicine  Houston Texas USA"},{"name":"Department of Pathology Michael E. DeBakey VA Medical Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Rivero","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2014Hematology and Oncology Baylor College of Medicine  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choladda V.","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology Baylor College of Medicine  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6515-1828","authenticated-orcid":false,"given":"Abdul Hafeez","family":"Diwan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology Baylor College of Medicine  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.02.001"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.02.011"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000441"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620714539906"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000862"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2017.6976"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14302"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219856422"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000980"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0457"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23775"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2020.2020.0120"},{"key":"e_1_2_6_15_1","first-page":"6154213","article-title":"Ibrutinib\u2010induced vasculitis in a patient with metastatic colon cancer treated in combination with cetuximab","volume":"2020","author":"Chi J","year":"2020","journal-title":"Case Rep Oncol Med"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14190"},{"key":"e_1_2_6_17_1","first-page":"S0190\u20109622(19)3","article-title":"Cutaneous eruptions from ibrutinib resembling EGFR inhibitor\u2010induced dermatologic adverse events","author":"Singer S","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00535-x"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cup.14160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cup.14160","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cup.14160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T23:24:43Z","timestamp":1693005883000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cup.14160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/cup.14160"],"URL":"https:\/\/doi.org\/10.1111\/cup.14160","archive":["Portico"],"relation":{},"ISSN":["0303-6987","1600-0560"],"issn-type":[{"value":"0303-6987","type":"print"},{"value":"1600-0560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"2021-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}